Skip to main content
. 2017 Sep 11;2017(9):CD006652. doi: 10.1002/14651858.CD006652.pub5

Comparison 1. Heparin versus placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1.1 Mortality at 12 months‐ Main analysis 18 9575 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.93, 1.03]
1.2 Mortality at 12 months‐ Subgroups Lung vs non‐Lung Cancer 12 4768 Risk Ratio (M‐H, Random, 95% CI) 0.94 [0.86, 1.03]
1.2.1 Lung Cancer (SCLC or NSCLC) 6 3204 Risk Ratio (M‐H, Random, 95% CI) 0.89 [0.73, 1.08]
1.2.2 non‐Lung Cancer 7 1564 Risk Ratio (M‐H, Random, 95% CI) 0.95 [0.88, 1.03]
1.3 Mortality at 12 months‐ Subgroups Advanced vs non‐Advanced 18 9575 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.94, 1.03]
1.3.1 Advanced cancer 12 6115 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.93, 1.02]
1.3.2 Non‐advanced cancer 8 3460 Risk Ratio (M‐H, Random, 95% CI) 0.92 [0.75, 1.12]
1.4 Mortality at 24 months‐ Main Analysis 14 5229 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.96, 1.01]
1.5 Mortality at 24 months‐ Subgroups Advanced vs non‐Advanced 14 5229 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.96, 1.01]
1.5.1 Advanced cancer 6 1554 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.93, 1.03]
1.5.2 Non‐advanced cancer 8 3675 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.93, 1.04]
1.6 Mortality over duration of study 15   Hazard Ratio (IV, Random, 95% CI) 0.93 [0.84, 1.03]
1.7 Symptomatic VTE‐ Main analysis 16 9036 Risk Ratio (M‐H, Random, 95% CI) 0.56 [0.47, 0.68]
1.8 Symptomatic VTE‐ Subgroups Lung vs non‐Lung Cancer 11 8090 Risk Ratio (M‐H, Random, 95% CI) 0.52 [0.43, 0.63]
1.8.1 Lung Cancer (SCLC or NSCLC) 6 4217 Risk Ratio (M‐H, Random, 95% CI) 0.53 [0.41, 0.68]
1.8.2 Non‐lung cancer 7 3873 Risk Ratio (M‐H, Random, 95% CI) 0.51 [0.37, 0.70]
1.9 PE 14 8867 Risk Ratio (M‐H, Random, 95% CI) 0.61 [0.47, 0.80]
1.10 Symptomatic DVT 14 8867 Risk Ratio (M‐H, Random, 95% CI) 0.46 [0.33, 0.63]
1.11 Major bleeding‐ Main analysis 18 9592 Risk Ratio (M‐H, Random, 95% CI) 1.30 [0.94, 1.79]
1.12 Major bleeding‐ Subgroups Lung vs non‐Lung Cancer 10 4163 Risk Ratio (M‐H, Random, 95% CI) 1.62 [1.02, 2.56]
1.12.1 Lung Cancer (SCLC or NSCLC) 5 3035 Risk Ratio (M‐H, Random, 95% CI) 1.45 [0.77, 2.73]
1.12.2 Non‐lung cancer 5 1128 Risk Ratio (M‐H, Random, 95% CI) 1.84 [0.94, 3.58]
1.13 Minor bleeding 16 9245 Risk Ratio (M‐H, Random, 95% CI) 1.70 [1.13, 2.55]
1.14 Thrombocytopenia 12 5832 Risk Ratio (M‐H, Random, 95% CI) 0.69 [0.37, 1.27]